BAM
VIR icon

Baldrige Asset Management’s Vir Biotechnology VIR Stock Holding History

Baldrige Asset Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		$0 Buy
+13
New +$332 ﹤0.01% 465

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Baldrige Asset Management's VIR Position: Q1 2023 in Review

Baldrige Asset Management opened a new position in Vir Biotechnology (VIR) in Q1 2023: 13 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #465 among its holdings.

231 funds tracked by Wall St. Rank hold VIR as of Q1 2023.

  • Baldrige Asset Management held 13 shares of Vir Biotechnology worth $0 as of Q1 2023.
  • Vir Biotechnology was a new Baldrige Asset Management position in Q1 2023.
  • Vir Biotechnology made up ﹤0.01% of Baldrige Asset Management's portfolio in Q1 2023, its #465 holding.
  • 231 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2023.

Based on Baldrige Asset Management's 13F filing for Q1 2023, filed 17 Apr 2023.